Dr Van der Heijden speaks to ecancer about CheckMate 901, which reviewed nivolumab plus gemcitabine-cisplatin versus gemcitabine-cisplatin alone for previously untreated unresectable or metastatic urothelial carcinoma (mUC).

The trial results were presented during the ESMO Congress 2023, held in Madrid, Spain.

The trial found that nivolumab plus gemcitabine-cisplatin showed statistically significant and clinically meaningful improvements in overall survival and patient free survival verus gemcitabine-cisplatin alone as first-line treatment for mUC.

He states that these results support nivolumab plus cisplatin-based chemotherapy as a new standard of care for patients with mUC.